Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

25.96 +0.36 (+1.41%)
Streaming Delayed Price Updated: 1:07 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Celldex Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Tech Rallies, Palantir Jumps 6% As Shutdown End Looms: What's Moving Markets Monday? ↗
Wall Street rebounded on Monday, recovering part of last week's steep losses as investors grew more confident about risk assets amid encouraging signs from Washington that the record-long government... 
Via Benzinga
News headline image
Celldex to Present at Upcoming Investor Conferences
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Analyst Expectations For Celldex Therapeutics's Future ↗
 
Via Benzinga
News headline image
Technical Breakout Setup for CELLDEX THERAPEUTICS INC (NASDAQ:CLDX) ↗
CLDX stock shows strong technical momentum and a high-quality consolidation pattern, suggesting a potential breakout above the $26.20 resistance level. 
Via Chartmill
News headline image
5 Analysts Assess Celldex Therapeutics: What You Need To Know ↗
 
Via Benzinga
News headline image
Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025
Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU 
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short ↗
Celldex will stop developing barzolvolimab in eosinophilic esophagitis after Phase 2 data showed strong mast cell reduction but no symptom improvement. 
Via Benzinga
News headline image
What Analysts Are Saying About Celldex Therapeutics Stock ↗
 
Via Benzinga
News headline image
La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Are Celldex Shares Tumbling After Hours? ↗
The biotech firm said it would halt development of barzolvolimab in eosinophilic esophagitis following Phase 2 results that met the trial’s primary goal but failed to show clinical benefit. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
These stocks are moving in today's after hours session ↗
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Celldex Therapeutics Inc (NASDAQ:CLDX) Q2 2025 Earnings: Revenue Misses, EPS Narrowly Beats Amid Strong Pipeline Progress ↗
Celldex Therapeutics Q2 2025 earnings: Revenue misses estimates at $730K, but EPS beats at -$0.85. Strong cash position supports pipeline, with key barzolvolimab trials progressing. 
Via Chartmill
News headline image
Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Celldex Study Finds Most Patients Symptom-Free From Angioedema After One Year; Retail Bulls Stay Guarded ↗
Celldex’s candidate targets KIT, a mast cell receptor tied to CSU inflammation, and had earlier met all key endpoints at 12 weeks. 
Via Stocktwits
News headline image
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
From Celldex Therapeutics, Inc.
Via GlobeNewswire
News headline image
Crude Oil Rises 6%; US Consumer Sentiment Surges In June ↗
 
Via Benzinga
News headline image
Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.